Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design

Meine, Rosanna GND; Becker, Walter; Falke, Hannes GND; Preu, Lutz GND; Loaëc, Nadège; Meijer, Laurent ORCID; Kunick, Conrad ORCID

Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a potential drug target because of its role in the development of Down syndrome and Alzheimer’s disease. The selective DYRK1A inhibitor 10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acid (KuFal194), a large, flat and lipophilic molecule, suffers from poor water solubility, limiting its use as chemical probe in cellular assays and animal models. Based on the structure of KuFal194, 7-chloro-1H-indole-3-carbonitrile was selected as fragment template for the development of smaller and less lipophilic DYRK1A inhibitors. By modification of this fragment, a series of indole-3-carbonitriles was designed and evaluated as potential DYRK1A ligands by molecular docking studies. Synthesis and in vitro assays on DYRK1A and related protein kinases identified novel double-digit nanomolar inhibitors with submicromolar activity in cell culture assays.


Citation style:
Meine, R., Becker, W., Falke, H., Preu, L., Loaëc, N., Meijer, L., Kunick, C., 2018. Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design.
Could not load citation form. Default citation form is displayed.

Access Statistic

Last 12 Month:


Use and reproduction: